Cosmetic cross-reference

Sparteine

CAS 90-39-1

Sparteine (CAS 90-39-1) is a Phase 4 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral / FAERS

Adverse signals

SOURCE IUPHAR / PharmGKB

PubMed IDs

SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Sparteine

CAS Number

90-39-1

UNII

298897D62S

InChIKey

SLRCCWJSBJZJBV-ZQDZILKHSA-N

ChEMBL ID

CHEMBL1908847

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural productwithdrawn flag

SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1908847 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE ChEMBL 36 activities + assays 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	22875.166666666668 nM	3	-
-	IC50	40500 nM	2	-
-	EC50	19700 nM	1	-
-	Potency	39810.7 nM	1	-

SOURCE PharmGKB drug-gene phenotypes 20 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

CYP2D6 (PA128) CYP2D6*4, CYP2D6*12

CYP2D6 *4/*12 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 8655150

CYP2D6 (PA128) CYP2D6*4, CYP2D6*59

CYP2D6 *4/*59 is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 17001296

CYP2D6 (PA128) CYP2D6*5, CYP2D6*7, CYP2D6*8

CYP2D6 *5/*7 + *5/*8 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 9511177

CYP2D6 (PA128) CYP2D6*4, CYP2D6*5, CYP2D6*6

CYP2D6 *4/*4 + *4/*5 + *4/*6 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 9511177

CYP2D6 (PA128) CYP2D6*5, CYP2D6*8

CYP2D6 *5/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 9241659

CYP2D6 (PA128) CYP2D6*4, CYP2D6*12

CYP2D6 *4/*12 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 9241659

CYP2D6 (PA128) CYP2D6*5, CYP2D6*7

CYP2D6 *5/*7 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 7845481

CYP2D6 (PA128) CYP2D6*4, CYP2D6*11

CYP2D6 *4/*11 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 9241659

CYP2D6 (PA128) CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10

CYP2D6 *4/*10 + *5/*10 + *10/*10 (assigned as intermediate metabolizers phenotype) are associated with decreased metabolism of sparteine in healthy individuals as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.

Evidence: -; PMID 9511177

CYP2D6 (PA128) CYP2D6*4, CYP2D6*6

CYP2D6 *4/*6 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of dextromethorphan or sparteine in healthy individuals.

Evidence: -; PMID 9241659

CYP2D6 (PA128) CYP2D6*4, CYP2D6*5

CYP2D6 *4/*5 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or sparteine in healthy individuals.

Evidence: -; PMID 9241659

CYP2D6 (PA128) CYP2D6*3, CYP2D6*4

CYP2D6 *4/*4 + *3/*4 are associated with decreased metabolism of debrisoquine or sparteine.

Evidence: -; PMID 2211621

CYP2D6 (PA128) CYP2D6*1, CYP2D6*4, CYP2D6*10

CYP2D6 *10/*10 + *4/*10 are associated with decreased metabolism of sparteine as compared to CYP2D6 *1/*1.

Evidence: -; PMID 8287064

CYP2D6 (PA128) CYP2D6*5, CYP2D6*8

CYP2D6 *5/*8 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of debrisoquine or sparteine in healthy individuals.

Evidence: -; PMID 8530011

CYP2D6 (PA128) CYP2D6*5, CYP2D6*18

CYP2D6 *5/*18 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 8946471

CYP2D6 (PA128) CYP2D6*41, CYP2D6*62

CYP2D6 *41/*62 is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 17460029

CYP2D6 (PA128) CYP2D6*4, CYP2D6*11

CYP2D6 *4/*11 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 8563771

CYP2D6 (PA128) CYP2D6*5, CYP2D6*7

CYP2D6 *5/*7 (assigned as poor metabolizers phenotype) is associated with decreased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 9241659

CYP2D6 (PA128) CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*35xN

CYP2D6 *35xN/*1 + *2xN/*2 are associated with increased metabolism of sparteine in healthy individuals.

Evidence: -; PMID 9511177

CYP2D6 CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*8, CYP2D6*10, CYP2D6*11, CYP2D6*12, CYP2D6*18, CYP2D6*35xN, CYP2D6*41, CYP2D6*59, CYP2D6*62

Evidence: 3; PMID 12

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Sparteine used for in pharmaceutical contexts?

Sparteine (CAS 90-39-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Sparteine?

No adverse-event association or SIDER side-effect rows are rendered for Sparteine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Sparteine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Sparteine with EU status "prohibited".

What clinical phase is Sparteine in?

Sparteine is rendered with ChEMBL max phase 4 (approved).